American Innovation and R&D Competitiveness Act of 2025
Summary
HR1990, the American Innovation and R&D Competitiveness Act, would restore immediate expensing for R&D costs, reversing the 2022 tax code change that required 5/15-year amortization. This is an early-stage bill referred to Ways and Means with 81 cosponsors, but if enacted, it would provide a direct 21% tax-rate cash flow benefit annually to every R&D-intensive US company. The largest absolute beneficiaries are mega-cap tech and pharma firms with $10B+ annual R&D budgets.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR1990 would restore immediate R&D expensing, directly increasing after-tax cash flow for every R&D-intensive US company by 21% of their R&D spend annually
- 2.Largest absolute beneficiaries are mega-cap tech and pharma with $10B+ R&D budgets: $AMZN, $GOOGL, $MSFT, $AAPL, $NVDA, $MRK, $LLY, $PFE
- 3.Bill is early stage (referred to Ways and Means), has 81 Republican cosponsors, no Senate companion — passage is not imminent and requires significant legislative momentum
Market Implications
A bill restoring immediate R&D expensing is structurally bullish for US R&D-intensive companies. The tax mechanism directly improves free cash flow by allowing companies to deduct R&D costs in Year 1 rather than spreading over 5 years. For $MSFT, $AAPL, and $NVDA — each with $10B-$30B in annual R&D — the cash flow benefit is $2-6B per year. For $AMZN, at $60B R&D, the annual benefit exceeds $12B. The bill is not priced into current valuations because of its early stage; passage would represent a meaningful tax cut for the growth sectors of the US economy. Failure to pass (or prolonged delay) maintains the current amortization regime, which is a headwind for high-R&D companies relative to the pre-2022 tax treatment.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Tax change: immediate expensing for R&D costs vs. current amortization requirement
Who must act
Companies filing US corporate tax returns with R&D expenditures qualifying under IRC §174
What happens
Reduction in taxable income by amount of annual R&D spend, improving after-tax cash flow by 21% of R&D expenses in year incurred
Stock impact
MSFT spent approximately $30B on R&D in FY2025; immediate expensing would reduce tax liability by ~$6.3B annually vs. current 5-year amortization schedule, directly improving free cash flow
What the bill does
Tax change: immediate expensing for R&D costs vs. current amortization requirement
Who must act
Companies filing US corporate tax returns with R&D expenditures qualifying under IRC §174
What happens
Reduction in taxable income by amount of annual R&D spend, improving after-tax cash flow by 21% of R&D expenses in year incurred
Stock impact
AAPL spent approximately $30B on R&D in FY2025; immediate expensing would reduce tax liability by ~$6.3B annually, significantly boosting net income and cash available for buybacks or investment
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
SCAM Act
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
BARNARD CONSTRUCTION COMPANY, INCORPORATED: $1.6B Department of Homeland Security Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Grid Infrastructure, Equipment, and Supply Chain Capacity
This Presidential Memorandum invokes Section 303 of the Defense Production Act (DPA) to address critical deficiencies in the domestic electric grid infrastructure and its supply chains. It authorizes the Secretary of Energy to make purchases, commitments, and provide financial support to expand the domestic capacity for designing, producing, and deploying grid infrastructure components like transformers, transmission lines, and related manufacturing tools, waiving certain DPA requirements for expediency.
Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Development, Manufacturing, and Deployment of Large-Scale Energy and Energy‑Related Infrastructure
This presidential memorandum invokes Section 303 of the Defense Production Act (DPA) to accelerate the development, manufacturing, and deployment of large-scale energy and energy-related infrastructure. It authorizes the Secretary of Energy to make necessary purchases, commitments, and financial instruments to expand domestic capabilities in this sector, citing a national energy emergency and the need to avert an industrial resource shortfall.